Bone Biologics launches $2M public offering

Bone Biologics, a company focused on spine fusion products, recently announced a $2 million public offering.

Advertisement

The public offering includes 781,251 shares of its common stock for $2.56 per share, according to a March 4 news release.

The company said it plans to use proceeds from the offering to support clinical trials, its patent portfolio and general corporate purposes, as well as for working capital.

Advertisement

Next Up in Biologics

Advertisement

Comments are closed.